EUVIMEDEUVIMED entdecken
Crossref

Four weeks of off‐treatment follow‐up is sufficient to determine virologic responses at off‐treatment week 12 in patients with hepatitis C virus infection receiving fixed‐dose pangenotypic direct‐acting antivirals

Chen-Hua Liu iD, Yu-Ping Chang, Ji-Yuh Lee, Chi-Yi Chen, Wei-Yu Kao, Chih-Lin Lin, Sheng-Shun Yang, Yu-Lueng Shih, Cheng-Yuan Peng, Fu-Jen Lee, Ming-Chang Tsai, Shang-Chin Huang und 5 weitere

Journal of Medical Virology · 2024

DOI: 10.1002/jmv.29675 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medical Virology, 2024. Verfasst von Chen-Hua Liu und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan. Hauptthemen laut MEDLINE: Antiviral Agents, Sustained Virologic Response, Hepacivirus, RNA, Viral. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Early confirmation of sustained virologic response (SVR) or viral relapse after direct‐acting antivirals (DAAs) for hepatitis C virus (HCV) infection is essential based on public health perspectives, particularly for patients with high risk of nonadherence to posttreatment follow‐ups. A total of 1011 patients who achieved end‐of‐treatment virologic response, including 526 receiving fixed‐dose pangenotypic DAAs, and 485 receiving other types of DAAs, who had available off‐treatment weeks 4 and 12 serum HCV RNA data to confirm SVR at off‐treatment week 12 (SVR 12 ) or viral relapse were included. The positive predictive value (PPV) and negative predictive value (NPV) of SVR 4 to predict patients with SVR 12 or viral relapse were reported. Furthermore, we analyzed the proportion of concordance between SVR 12 and SVR 24 in 943 patients with available SVR 24 data. The PPV and NPV of SVR 4 to predict SVR 12 were 98.5% (95% confidence interval [CI]: 98.0–98.9) and 100% (95% CI: 66.4–100) in the entire population. The PPV of SVR 4 to predict SVR 12 in patients receiving fixed‐dose pangenotypic DAAs was higher than those receiving other types of DAAs (99.8% [95% CI: 98.9–100] vs. 97.1% [95% CI: 96.2–97.8], p < 0.001). The NPVs of SVR 4 to predict viral relapse were 100%, regardless of the type of DAAs. Moreover, the concordance between SVR 12 and SVR 24 was 100%. In conclusion, an off‐treatment week 4 serum HCV RNA testing is sufficient to provide an excellent prediction power of SVR or viral relapse at off‐treatment week 12 among patients with HCV who are treated with fixed‐dose pangenotypic DAAs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsSustained Virologic ResponseHepacivirusRNA, ViralHepatitis C, ChronicHumansMaleFemaleMiddle AgedAgedAdultRecurrenceFollow-Up StudiesTreatment OutcomeHepatitis C

Stichwörter der Autor:innen

direct‐acting antiviralhepatitis C viruspangenotypicsustained virologic response

Substanzen

Antiviral AgentsRNA, Viral

Autor:innen und Institutionen

  • Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
  • Hepatitis Research Center, National Taiwan University Hospital, Taipei, Taiwan.
  • Department of Internal Medicine, National Taiwan University Hospital, Yun-Lin Branch, Yunlin, Taiwan.
  • Department of Internal Medicine, Division of Gastroenterology and Hepatology, Ditmanson Medical Foundation Chiayi Christian Hospital, Chiayi, Taiwan.
  • Department of Internal Medicine, Division of Gastroenterology and Hepatology, Taipei Medical University Hospital, Taipei, Taiwan.
  • Department of Internal Medicine, School of Medicine, Division of Gastroenterology and Hepatology, College of Medicine, Taipei Medical University, Taipei, Taiwan.

ORCID-Profile: Chen-Hua Liu

Zitieren

APA

Liu, C. H., Chang, Y. P., Lee, J. Y., Chen, C. Y., Kao, W. Y., Lin, C. L., Yang, S. S., Shih, Y. L., Peng, C. Y., Lee, F. J., Tsai, M. C., Huang, S. C., Su, T. H., Tseng, T. C., Liu, C. J., Chen, P. J., & Kao, J. H. (2024). Four weeks of off‐treatment follow‐up is sufficient to determine virologic responses at off‐treatment week 12 in patients with hepatitis C virus infection receiving fixed‐dose pangenotypic direct‐acting antivirals. Journal of Medical Virology. https://doi.org/10.1002/jmv.29675

Vancouver

Liu CH, Chang YP, Lee JY, Chen CY, Kao WY, Lin CL, et al. Four weeks of off‐treatment follow‐up is sufficient to determine virologic responses at off‐treatment week 12 in patients with hepatitis C virus infection receiving fixed‐dose pangenotypic direct‐acting antivirals. Journal of Medical Virology. 2024. doi:10.1002/jmv.29675

BibTeX
@article{Liu2024,
  author = {Liu, Chen-Hua and Chang, Yu-Ping and Lee, Ji-Yuh and Chen, Chi-Yi and Kao, Wei-Yu and Lin, Chih-Lin and Yang, Sheng-Shun and Shih, Yu-Lueng and Peng, Cheng-Yuan and Lee, Fu-Jen and Tsai, Ming-Chang and Huang, Shang-Chin and Su, Tung-Hung and Tseng, Tai-Chung and Liu, Chun-Jen and Chen, Pei-Jer and Kao, Jia-Horng},
  title = {Four weeks of off‐treatment follow‐up is sufficient to determine virologic responses at off‐treatment week 12 in patients with hepatitis C virus infection receiving fixed‐dose pangenotypic direct‐acting antivirals},
  journal = {Journal of Medical Virology},
  year = {2024},
  doi = {10.1002/jmv.29675}
}
Kostenlos starten →